Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

BACKGROUND: Response rates to single agent immune checkpoint blockade in unselected pretreated HER2−negative metastatic breast cancer (MBC) are low. However, they may be augmented when combined with chemotherapy. METHODS: We conducted a single-arm, phase II study of patients with triple negative (TN...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Ami N, Flaum, Lisa, Helenowski, Irene, Santa-Maria, Cesar A, Jain, Sarika, Rademaker, Alfred, Nelson, Valerie, Tsarwhas, Dean, Cristofanilli, Massimo, Gradishar, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057426/
https://www.ncbi.nlm.nih.gov/pubmed/32060053
http://dx.doi.org/10.1136/jitc-2019-000173